New Jersey-based Cambrex closed on its $425 million acquisition of dosage-form CDMO Halo Pharma and the two manufacturing plants picked up in the deal.
Cambrex announced the acquisition of Halo from SK Capital, which has a number of CDMO holdings, in July.
“The acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combines business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” Steve Klosk, president and chief executive of Cambrex, said in a statement.
Halo operates manufacturing sites in Whippany, New Jersey, and Montreal, comprising a total of 430,000 square feet of plant space. Its 450-person workforce will join Cambrex’s 1,200 employees across the U.S. and Europe.
SK Capital has been in the midst of a lot of consolidation in the CDMO market. Last year, Perrigo sold off its active pharmaceutical business to the investment group for $110 million.